seekingalpha.com
Fagron NV (ARSUF) Q4 2025 Earnings Call Transcript
Fagron NV (ARSUF) Q4 2025 Earnings Call Transcript
ARSUFARSUFOTC
Loading
Latest News
Loading news...
seekingalpha.com
Fagron NV (ARSUF) Q3 2025 Sales Call Transcript
Fagron NV (OTCPK:ARSUF) Q3 2025 Sales Call October 9, 2025 3:30 AM EDT Company Participants Ignacio Artola Rafael Padilla - CEO & Executive Director Karin de Jong - CFO & Executive Director Conference Call Participants Stijn Demeester - ING Groep N.V., Research Division Frank Claassen - Banque Degroof Petercam S.A.
seekingalpha.com
Fagron: Recent Capital Markets Day Confirms Upside Potential
Fagron, a Belgian pharmaceutical compounding leader, has resolved previous market concerns and provided optimistic 2025-2030 guidance, projecting significant revenue and margin growth. The company expects high single to low double-digit organic revenue growth and improved margins, maintaining leverage ratios within a 2.8-3.5 times EBITDA range. Two scenarios project 2024-2030 revenue growth of 7.5% and 11%, leading to potential REBITDA of 293M EUR and 350M EUR, respectively.
seekingalpha.com
Fagron: FDA Warning Letter Creates New Entry Opportunity
Fagron: FDA Warning Letter Creates New Entry Opportunity
seekingalpha.com
Fagron NV (ARSUF) Q2 2023 Earnings Call Transcript
Fagron NV (OTC:ARSUF) Q2 2023 Earnings Conference Call August 3, 2023 3:30 AM ET Company Participants Karen Berg - Investor Relations Rafael Padilla - Chief Executive Officer Karin de Jong - Chief Financial Officer Conference Call Participants Stijn Demeester - ING Frank Claassen - Degroof Petercam Alexander Craeymeersch - Kepler Cheuvreux Chase Coughlan - Van Lanschot Kempen Maarten Verbeek - The Idea Operator Hello and welcome to the Fagron Half Year 2023 Results. My name is Caroline, and I will be your coordinator for today's event.